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Structural studies of some of the most interesting biologi-
cal macromolecules are frequently aborted because of an
inability to form suitably diffracting crystals. Although
advances have been made in crystallizing soluble and
membrane proteins [1-6], crystallization is frequently
inhibited by heterogeneity, insolubility, molecular flexibil-
ity or a polydisperse character in solution. Viral capsid
subunits and membrane proteins are, for example, mem-
bers of this intransigent group. Current crystallization
tools include commercial crystallization kits [7-11], sparse
matrix sampling [12], crystallization robots [13], surveys
of crystallization data bases [14] and seeding techniques
[15]. A useful addition to this growing repertoire is co-
crystallization with antibody fragments such as Fab or Fvs.
Fab fragments have reasonable solubility and bind specifi-
cally to selected antigens with equilibrium constants in
the range of 105 to 108 M-l [16]. An Fab-antigen com-
plex is therefore likely to have suitable properties for
forming crystals (Table 1). Thus, they can effectively
transform aggregated material into a soluble, mono-
disperse sample suitable for crystallization. Laver [17]
observed that some proteins can be crystallized only
when complexed with a cognate Fab fragment. This
approach can sometimes be applied more readily than
molecular engineering of point mutants or truncations
to obtain a modified protein with improved crystalliza-
tion properties. Furthermore, antibodies are frequently
available from related biochemical studies.
An early use of an antibody specifically for crystallizing
an otherwise insoluble protein was for the crystallization
of HIV capsid protein p24 [18]. Dimers of recombinant
human immunodeficiency virus (HIV) capsid protein
p24 associate into large oligomers with a complex distri-
bution of sizes [19]. Although this oligomerization is
appropriate for the protein as it forms the -1000 A long
core of the HIV virion, this property interfered with
attempts to crystallize the protein. Detergents, such as
P3-octyl-glucoside, decreased aggregation but alone were
inadequate for obtaining crystals. Only after screening
crystallization conditions with several different Fab frag-
ments that recognize different p24 epitopes were crystals
obtained that were suitable for X-ray diffraction analysis.
A subsequent example of the use of a Fab fragment to
crystallize a protein was that of HIV reverse transcriptase
(RT) [20,21], which was crystallized as a ternary com-
plex of RT-Fab-DNA. In this case, the Fab was thought
to act as a 'molecular clamp' that immobilized a region of
the enzyme. Although other structures of RT were
obtained without the use of a Fab, its inclusion in
RT-Fab-DNA complex resulted in a particularly rapid
structure determination [21].
Use of Fv instead of Fab fragments is likely to have some
advantages as there will be no flexible elbow to
inhibit crystallization. The most recent example of an anti-
body-protein complex utilized an Fv fragment to crystal-
lize cytochrome c oxidase, a membrane protein, from
Paracoccus denitritcans [22,23]. The Fv fragment recognizes
the periplasmic domain of the oxidase, but does not substi-
tute for the membrane portion. Instead, the polar surface
of the oxidase is increased by complex formation, thereby
permitting formation of the major lattice packing contacts.
Preparation of complex crystals
Practical aspects of crystallizing antigen-antibody com-
plexes involve selection of the antibody, preparation of a
homogenous Fab species and the preparation of a com-
plex with proper stoichiometry. The ideal antibody
should not alter the native antigen conformation or
interfere with its biological activity. For proteins that
have a measurable enzymatic activity, conformation can
be inferred by assaying the activity in the presence of the
Fab. In the case of the HIV RT [20], the monoclonal
antibody was selected that had the highest avidity to the
RT heterodimer. In contrast, the HIV p24 crystallization
trials were set up with Fabs recognizing different epitopes.
Bead-immobilized papain is particularly convenient for
Fab preparation as the protease can be removed by cen-
trifugation or filtration. The progress of digestion can be
monitored by examining aliquots with reducing and
non-reducing SDS-PAGE to find the conditions that
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Table 1. Antibody-protein antigen complexes studied
crystallographically.
Protein Antibody References
fragment
Lysozyme* D1.3 29
Lysozyme* HyHEL-5 30
Lysozyme* HyHEL-10 31
Lysozyme* F9.13.7 32
Neuraminidase* NC41 33
Human rhinovirus 14* F17-lA 34
HIV-1 reverse transcriptaset Fab28 21
HIV-1 capsid protein p24t Fab25.3 19
Cytochrome c oxidase t Fv7E2 23
*In these complexes the Fab was used to study
antigen-antibody interactions. t in these complexes the Fab
was used as a crystallization tool to aid in the structure
determination of the protein antigen.
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Fig. 1. Fab purification using a linear programmed pH gradient,
from 8.0 to 5.8, for elution from a Pharmacia MonoQ column.
Nine different fractions of the Fb could be recognized, but only
fraction VII crystallized easily when complexed with HIV p24.
maximize Fab production. Following the papain treat-
ment, the F portion must be removed by, for instance,
anion-exchange chromatography with a NaCI gradient.
The Fab fragment used to crystallize HIV p24 could be
further resolved into nine fractions (Fig. 1) by ion-
exchange chromatography using a pH gradient. Eight of
these nine fractions were able to form a complex with
HIV p24 in solution, shown by native, or isoelectric
focusing (IEF), gel analysis, although only one of these
complexes gave useful crystals. Unfortunately, the single
Fab species that crystallized represented only about 15%,
by weight, of the total Fab isolated from cell culture.
Native gel electrophoresis can assay whether the purified
Fab fragment has retained its antigen-binding capacity
(Fig. 2). IEF gels are also useful for determining the opti-
mal stoichiometry, by examining mixtures with different
ratios of Fab to antigen. If the isoelectric points of the Fab
and antigen are different, then it should be possible to
resolve the Fab, the complex and the antigen. The best
stoichiometry should be that ratio with the least intense
bands for the individual components.
It is necessary to have determined the amino-
acid sequence of the light and heavy chain variable
domains before interpreting the electron density of
the antigen-antibody complex. The resultant cDNA
sequencing represents an additional investment of time.
Sequence determination [24] for the Fab used for crystal-
lization of HIV p24 (derived from a mouse IgG 1 with a
k light chain) was accomplished with the 'Ig-Prime'
kit purchased from Novagen Inc. (597 Science Drive,
Madison, WI 53711).
The amino-acid sequence of the Fv (murine IgG1, k)
fragment that interacts with the integral membrane pro-
tein cytochrome c oxidase shows an unusual cysteine
residue in the complimentarity-determining region
(CDR)-H2 at position H50. Michel and co-workers
Fig. 2. Native PAGE gel (8% to 25% cross-linked) analysis of
molar ratios of HIV p24 and Fab. The p24 and Fab superimpose
on the same band, but the p24 -Fab complex exhibits retarded
migration. A molar ratio of two p24s to one Fab appears to be the
correct stoichiometry, although they occur as a 1:1 ratio in the
crystal structure.
presumed that this cysteine, which is not involved in
disulfide bond formation, might be the cause of low
recovery of the Fv fragment from the Escherichia coli
periplasmic space. After mutating this residue to a serine,
the amount of Fv that could be purified increased approx-
imately 20-fold [25] while the binding characteristics to
cytochrome c oxidase remained unaltered.
The development of recombinant DNA technology for
immunodiagnostic and immunotherapeutic applications
is likely to lead to simpler methods for producing Fv frag-
ments. Phage display technology [26,27] coupled with a
large combinatorial immunoglobulin library, can also
rapidly produce a large number of monoclonal antibodies
against a given antigen [28].
Other benefits derived from crystallizing a Fab-antigen
complex
The presence of a Fab or Fv fragment in the crystal can
aid in the crystallographic structure determination itself,
as the fragment can be used for molecular replacement or
as a recipient of heavy atom labels. Unfortunately, the
molecular replacement phases, based on the cognate Fab,
in the structure determination of HIV p24, were insuffi-
cient to solve the structure. They had to be augmented
by multiple isomorphous replacement phases, single
wavelength anomalous dispersion of a lead derivative and
averaging over the two non-crystallographically related
complexes in the asymmetric unit of the crystal. It may
also be useful to crystallize the Fab fragment on its own
and use the resultant structure as the molecular replace-
ment model, although the elbow angle is likely to differ
in different environments. In the structure determination
of HIV-p24, the Fab fragment also served to identify the
p2 4 electron density associated with the residues known
to be the epitope for Fab binding.
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The crystal lattice contacts were primarily between the
Fv or Fab fragments in the structure determinations of the
cytochrome c oxidase and HIV p24, respectively.
Although this was an advantage in the former, it was
a problem in the latter where the occupancy of the
antigen within the Fab crystal lattice was incomplete and
variable. However, particularly for small, single domain,
monomeric proteins, the formation of a crystal lattice
based only on contacts between the larger and more
soluble Fab fragments is likely to be an advantage.
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